SNS 01

Drug Profile

SNS 01

Alternative Names: SNS-01; SNS-01-T; SNS-101

Latest Information Update: 06 Jan 2016

Price : $50

At a glance

  • Originator Senesco Technologies
  • Developer Senesco Technologies; Sevion Therapeutics
  • Class Antineoplastics; Gene therapies; Small interfering RNA
  • Mechanism of Action Apoptosis stimulants; Cell adhesion molecule inhibitors; Eukaryotic initiation factor 5A modulators; NF-kappa B inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Multiple myeloma; Diffuse large B cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Diffuse large B cell lymphoma; Lung cancer; Mantle-cell lymphoma; Multiple myeloma

Most Recent Events

  • 17 Nov 2014 Suspended - Phase-I/II for Diffuse large B cell lymphoma (Second-line therapy or greater) in South Africa (IV)
  • 17 Nov 2014 Suspended - Phase-I/II for Diffuse large B cell lymphoma (Second-line therapy or greater) in USA (IV)
  • 17 Nov 2014 Suspended - Phase-I/II for Mantle cell lymphoma (Second-line therapy or greater) in South Africa (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top